OUR FORMULATIONS PORTFOLIO


AAHI’s robust adjuvant formulation portfolio allows collaborators to select an adjuvant formulation that maximizes the impact of a specific vaccine candidate.

loader-icon

TLR Ligands + Alum

What is it?

The adsorption of TLR ligands to Alum, which shifts immune response to Th1 quality.

Where does it come from?

AAHI developed a formulation approach to adsorb lipid-based TLR ligands to Alum.

Unique to AAHI

AAHI’s formulations of both TLR 4 ligands and TLR 7/8 ligands adsorbed to Alum are tested in humans.

Resources

3M-052-Alum Adjuvant Portfolio

Vaccine Adjuvant Compendium, NIH

NanoAlum

What is it?

NanoAlum consists of nanoparticle rods of aluminum oxyhydroxide

Where does it come from?

AAHI developed NanoAlum using a top-down manufacturing approach starting with commercial Alum (Alhydrogel®)

Unique to AAHI

NanoAlum enhances Th1-type adjuvant activity compared to Alum, can be sterile-filtered and is stable to freeze-thaw

Resources

Aqueous Nanosuspension

What is it?

Aqueous nanosuspensions of TLR ligands (e.g. GLA-AF) suitable for intradermal delivery.

Unique to AAHI

The manufacturing process of aqueous nanosuspensions is straightforward and the cost of goods is low.

Resources

TLR4 Ligands

What is it?

GLA and SLA are synthetic hexa-acylated monophosphoryl lipid A molecules with established safety and activity profile from Phase 1/2 clinical testing.

Where does it come from?

GLA and SLA were designed as synthetic analogues to the hexa-acylated component of the naturally derived MPL®

Unique to AAHI

GLA and SLA are highly pure defined compounds designed for optimal TLR4 receptor binding, enabling substantially lower clinical dose compared to MPL®. In a squalene emulsion, they can also be lyophilized for single vial thermostable presentation or can be spray dried for thermostable nasal dry powder delivery.

Resources

TLR7/8 Ligands

What is it?

3M-052 (TLR7/8) is synthetic lipidated imidazoquinoline.

Where does it come from?

Developed by 3M and licensed to AAHI for specific indications.

Unique to AAHI

3M-052 formulations developed by AAHI elicit exceptional response durability with strong Th1 bias in NHPs.

Resources

Saponin QS-21

What is it?

QS-21 is a saponin derived from Quillaja Saponaria associated with inflammasome activation.

Where does it come from?

cGMP QS-21 is obtained by AAHI from bark extract at high yield and high purity using a novel purification process.

Unique to AAHI

AAHI’s QS-21 has been formulated in liposomes with GLA and tested in Phase 1 clinical trials.

Resources

Dual Agonist

What is it?

GLA-3M-052-LS is a dual TLR ligand liposome adjuvant.

Where does it come from?

GLA-3M-052-LS was developed by AAHI in collaboration with 3M and the University of Virginia using an amebiasis vaccine candidate as a proof-of-concept.

Unique to AAHI

This dual agonist develops a strong mucosal immune response as well as a Th1 type systemic response.

Resources

FORMULATIONS PIPELINE

AAHI’S adjuvant technology has been clinically tested in nearly 10,000 human volunteers and has an outstanding safety profile. 

ADJUVANT

Preclinical

GMP/Tox

Phase 1

Phase 2

Phase 3

Squalene Emulsion

SE




TLR 4 Agonists





GLA-AF/Alum





SLA-SE




TLR/ 7/8 Agonists





3M-052-SE




TLR 4 Agonists + Saponin

GLA-LSQ





SLA-LSQ




Dual Agonist

GLA-3M-052-LS





RNA DELIVERY VEHICLE

Preclinical

GMP/Tox

Phase 1

Phase 2

Phase 3

Nanostructured Lipid Carrier

NLC




Find out how our adjuvant formulations are revolutionizing vaccines and immunotherapies worldwide.